IGF-1 DES

IGF-1 DES (short for des(1-3)IGF-1) is a naturally occurring, truncated form of insulin-like growth factor 1 that is studied in the laboratory as a more potent IGF-1 variant. It is identical to native IGF-1 except that it is missing the first three amino acids at one end of the chain — a small change with an outsized effect on how the molecule behaves.

What is IGF-1 DES?

IGF-1 DES is a 67‑amino-acid peptide derived from insulin-like growth factor 1 (IGF-1) by removing the N-terminal tripeptide glycine-proline-glutamate (Gly-Pro-Glu, residues 1–3). That is the entire structural difference between the two molecules — hence the name “des(1-3).” It is not a wholly synthetic invention: des(1-3)IGF-1 occurs naturally in human brain tissue and bovine colostrum and is generated when enzymes clip the N-terminus off circulating IGF-1.

Removing those three residues sharply lowers the peptide’s affinity for the IGF-binding proteins (IGFBPs), especially IGFBP-3, which normally bind and sequester the great majority of IGF-1 in circulation. Because IGF-1 DES escapes that buffering, more of it remains free and able to engage its receptor — the basis for its higher apparent potency in several animal models.

How IGF-1 DES is studied to work

IGF-1 DES is thought to act through the same receptor system as IGF-1, but to reach it more efficiently. In circulation, roughly 95–98% of IGF-1 is bound to IGFBPs and is effectively held in reserve. With its binding-protein affinity reduced, IGF-1 DES stays largely free, binds the type‑1 IGF receptor (IGF-1R), and triggers the canonical IGF/insulin signaling cascade.

• IGF-1 receptor (IGF-1R): the primary target, a receptor tyrosine kinase that autophosphorylates on activation.
• Reduced IGFBP sequestration: the defining pharmacodynamic feature — weak IGFBP-3 binding leaves more free, receptor-available peptide.
• PI3K → AKT/PKB pathway: drives cell survival, protein synthesis (anabolic signaling) and glucose uptake.
• Ras → MEK → ERK/MAPK pathway: drives cell proliferation, growth and gene transcription.
• IRS-1/IRS-2 and Shc adaptors: recruited at the activated receptor to launch those downstream pathways.

Reported effects and benefits in the research literature

The findings below come from cell-culture and animal studies. They describe what researchers have measured in those models — not established outcomes in people.

• Greater potency than IGF-1 in vivo: in GH-deficient (lit/lit) mice, des(1-3)IGF-1 was reported up to roughly 10-fold more potent than IGF-1 (Gillespie 1990), though the differential is smaller in other assays.
• Anabolic effects in catabolic states: in dexamethasone-treated and diabetic rats, IGF-1 variants including des(1-3)IGF-1 increased weight gain, nitrogen retention and muscle protein synthesis; des(1-3)IGF-1 was about 2.5-fold more potent than IGF-1 in one catabolic-rat model (Tomas 1992).
• Tissue growth: enhanced gut growth after intestinal resection in rats.
• Cell proliferation: stimulated DNA synthesis in cultured myoblasts and fibroblasts at lower concentrations than full-length IGF-1.

What this does NOT mean: none of these results demonstrate muscle growth, recovery, anti-aging or performance benefits in humans. All efficacy data are preclinical, and as an IGF-1R agonist the peptide carries theoretical proliferative and blood-sugar considerations that are uncharacterized in people.

What the human evidence shows

There is essentially no human clinical evidence for IGF-1 DES as a therapeutic. It has no FDA approval for any use and is handled strictly as a laboratory research reagent; no clinical trials of the peptide itself as a drug were identified. (Note that full-length recombinant IGF-1, mecasermin/Increlex, is a separate, approved medicine — IGF-1 DES is not that molecule and is not approved.) IGF-1 and its analogues, including des(1-3)IGF-1, are also prohibited at all times in sport under Section S2 of the WADA Prohibited List.

Handling, storage and reconstitution (research context)

• Lyophilized powder: typically stored at −20 °C (long-term −20 °C to −80 °C), protected from light and moisture.
• Reconstituted solution: refrigerate at 2–8 °C and use within a short window (commonly cited as ~2–4 weeks); avoid repeated freeze–thaw cycles.
• Concentration math: work in mg/mL, not “units.” Our reconstitution calculator converts vial amount and diluent volume into concentration, and the explainer on why units are not a dose covers the common syringe-reading mistake.
• Always follow the specific product’s Certificate of Analysis (COA) and label.

Cautions and considerations

• Research compound only — not FDA-approved, not a medicine, and not for human or veterinary use.
• No established human dosing, safety or efficacy.
• Prohibited in sport (WADA Section S2) at all times.
• Purity and identity vary by source — a third-party COA (mass spec / HPLC) is essential, and net peptide content matters for accurate concentration.
• Informational and educational content only — not medical advice. Audience 21+.

Frequently asked questions

How is IGF-1 DES different from IGF-1 LR3?

Both are IGF-1 analogues engineered to evade binding proteins, but differently. IGF-1 DES is truncated — it removes the first three residues, giving a 67-amino-acid peptide. IGF-1 LR3 instead adds a 13-amino-acid N-terminal extension and swaps one residue, producing a longer peptide with a substantially longer half-life.

Is IGF-1 DES FDA-approved?

No. It has no FDA approval for any use and is treated as a research reagent. Native full-length IGF-1 (mecasermin/Increlex) is a separate, approved drug — IGF-1 DES is not that molecule.

Why is IGF-1 DES considered more potent than regular IGF-1?

Because it binds IGF-binding proteins (especially IGFBP-3) weakly, so more of it stays free and active; in some animal models that translated to roughly 10-fold greater potency than IGF-1.

Is IGF-1 DES banned in sports?

Yes. IGF-1 and its analogues, including des(1-3)IGF-1, are prohibited at all times under Section S2 of the WADA Prohibited List.

Related compounds and further reading

• How to reconstitute peptides — step-by-step research-handling guide.
• Sterile technique — clean handling and contamination prevention.
• IGF-1 LR3 — the long-acting, N-terminally extended IGF-1 analogue.
• MK-677 (Ibutamoren) — an oral growth-hormone secretagogue often discussed alongside IGF-1 compounds.
• Browse the full peptide library and the handling guides.

For informational use only. Not medical advice; consult a qualified healthcare professional. 21+.